Cover Image
市場調查報告書

慢性冠狀動脈疾病(CAD)(缺血性心臟疾病) : 開發中產品分析

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 321903
出版日期 內容資訊 英文 207 Pages
訂單完成後即時交付
價格
Back to Top
慢性冠狀動脈疾病(CAD)(缺血性心臟疾病) : 開發中產品分析 Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017
出版日期: 2017年03月08日 內容資訊: 英文 207 Pages
簡介

慢性冠狀動脈疾病(CAD)是最常見的心臟疾病。是膽固醇等物質堆積在將血液送往心臟的冠狀動脈內壁,造成血管壁硬化、狹窄而引發的疾病。最常見的症狀有心絞痛、胸部疼痛、其他還有呼吸急促、心悸、心搏過速、暈眩、噁心、發汗等。

本報告提供慢性冠狀動脈疾病(CAD)(缺血性心臟疾病)的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

慢性冠狀動脈疾病(CAD)(缺血性心臟疾病)概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

開發中產品的概要

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

開發中的產品:各企業

開發治療藥的企業

  • Gilead Sciences, Inc.
  • Human Stem Cells Institute
  • Juventas Therapeutics, Inc.
  • Lacer, S.A.
  • Nuo Therapeutics, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • ALD-201
  • Biglycan Therapy for Cardiovascular Diseases
  • Cryocell
  • Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Diseases
  • JVS-100
  • LA-419
  • Oligonucleotides for Ischemic Heart Disease and Duchenne Muscular Dystrophy
  • ranolazine ER

最新的開發中產品資訊

開發暫停中的計劃

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9017IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 3, 17, 7, 18 and 1 respectively. Similarly, the Universities portfolio in IND/CTA Filed and Discovery stages comprises 1 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
    • advanceCor GmbH
    • Akcea Therapeutics Inc
    • Amarantus Bioscience Holdings Inc
    • AnGes MG Inc
    • Arena Pharmaceuticals Inc
    • Ascendia Pharmaceuticals LLC
    • AstraZeneca Plc
    • Athera Biotechnologies AB
    • Bayer AG
    • Biscayne Pharmaceuticals Inc
    • Capricor Therapeutics Inc
    • Cardiome Pharma Corp
    • CardioVascular BioTherapeutics Inc
    • Cerenis Therapeutics Holding SA
    • CSL Ltd
    • Esperion Therapeutics Inc
    • Gilead Sciences Inc
    • HitGen LTD
    • Human Stem Cells Institute
    • Japan Tobacco Inc
    • Juventas Therapeutics Inc
    • Lee's Pharmaceutical Holdings Ltd
    • LipimetiX Development Inc
    • Lonestar Heart Inc
    • MedImmune LLC
    • Merck & Co Inc
    • Nuo Therapeutics Inc
    • Pfizer Inc
    • Pharmahungary Group
    • Proteon Therapeutics Inc
    • Resverlogix Corp
    • Tasly Pharmaceutical Group Co Ltd
    • The Medicines Company
    • Verseon Corp
    • VESSL Therapeutics Ltd
    • ViroMed Co Ltd
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles
    • 4-WF - Drug Profile
    • AEM-28 - Drug Profile
    • AEM-2802 - Drug Profile
    • ALD-201 - Drug Profile
    • alprostadil - Drug Profile
    • AMRS-001 - Drug Profile
    • anacetrapib - Drug Profile
    • apabetalone - Drug Profile
    • AZD-5069 - Drug Profile
    • AZD-5718 - Drug Profile
    • beperminogene perplasmid - Drug Profile
    • Biologics for Acute Coronary Syndrome - Drug Profile
    • BIS-5409 - Drug Profile
    • bivalirudin - Drug Profile
    • cangrelor tetrasodium - Drug Profile
    • CAP-1002 - Drug Profile
    • CAP-2003 - Drug Profile
    • CER-001 - Drug Profile
    • clopidogrel bisulphate - Drug Profile
    • COR-2 - Drug Profile
    • Cryocell - Drug Profile
    • CSL-112 - Drug Profile
    • CVBT-141H - Drug Profile
    • dalcetrapib - Drug Profile
    • Gemacell - Drug Profile
    • Gene Therapy to Activate Vascular Endothelial Growth Factor for Coronary Artery Disease - Drug Profile
    • IONIS-APOARX - Drug Profile
    • JVS-100 - Drug Profile
    • MEDI-6012 - Drug Profile
    • MultiGeneAngio - Drug Profile
    • MZ-004 - Drug Profile
    • Neovasculgen - Drug Profile
    • PC-mAb - Drug Profile
    • PF-06282999 - Drug Profile
    • PMC-6 - Drug Profile
    • PR-15 - Drug Profile
    • Proteins for Ischemic Heart Disease - Drug Profile
    • ranolazine ER - Drug Profile
    • Recombinant Protein for Cardiovascular Diseases - Drug Profile
    • Rejuveinix - Drug Profile
    • rivaroxaban - Drug Profile
    • Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile
    • Small Molecules to Inhibit PCSK9 for Acute Coronary Syndrome and Atherosclerosis - Drug Profile
    • Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile
    • temanogrel hydrochloride - Drug Profile
    • tirofiban hydrochloride - Drug Profile
    • TSL-0202 - Drug Profile
    • vericiguat - Drug Profile
    • VM-202 - Drug Profile
    • vonapanitase - Drug Profile
    • ZK-001 - Drug Profile
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017 (Contd..1), H1 2017
  • Products under Development by Companies, H1 2017 (Contd..2), H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by advanceCor GmbH, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Akcea Therapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AnGes MG Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Arena Pharmaceuticals Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Biscayne Pharmaceuticals Inc, H1 2017
  • 1`
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cardiome Pharma Corp, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cerenis Therapeutics Holding SA, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Esperion Therapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by HitGen LTD, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Japan Tobacco Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Juventas Therapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Lonestar Heart Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Merck & Co Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Nuo Therapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pfizer Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Pharmahungary Group, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..2), H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2017 (Contd..3), H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017
  • Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2017 (Contd..1), H1 2017

List of Figures

  • Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Top 10 Routes of Administration, H1 2017
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2017
  • Number of Products by Top 10 Molecule Types, H1 2017
  • Number of Products by Stage and Top 10 Molecule Types, H1 2017
Back to Top